Pharmaceutical Technology

OCTOBER 5, 2022

According to GlobalData’s analyst consensus forecast, Yescarta is expected to reach peak sales of $1.8bn in 2028, and Kymriah is expected to reach sales of $686m in the same year. From a clinical perspective, CAR-T therapy may not be appropriate for patients who are typically eligible for cell therapies.

In-Vitro 279

In-Vitro In-Vivo Sales Clinical Trials 279

Pharmaceutical Technology

APRIL 25, 2023

sCFH is an engineered and improved version of complement factor H (CFH) that can fit into adeno-associated virus (AAV) vectors with solid expression and applications confirmed in cultured human cells in vitro, in addition to various preclinical animal models in vivo. The firm will also receive single-digit royalties on net sales.

In-Vivo 130

In-Vivo In-Vitro Sales Engineer 130

Pharmaceutical Technology

MAY 31, 2023

In vivo and in vitro pre-clinical studies demonstrated that CFT8919 provides wider coverage of on-target resistant mutations and intracranial activity, indicating its potential to be effective against brain metastases. The company will also secure low single-digit percentage royalties on net sales outside these territories.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

Pharmaceutical Technology

FEBRUARY 28, 2023

Eucure Biopharma will receive up to $28.17m (¥196m) in potential sales milestone payment and tiered royalties on net sales. The bispecific antibody was found to conditionally activate the immune pathway in the tumour microenvironment in vitro and in vivo trials.

In-Vivo 130

In-Vivo Antibody In-Vitro Licensing 130

pharmaphorum

FEBRUARY 19, 2021

CEO is Daniel Dornbusch, who used to be Americas sales director for Novartis and CEO and co-founder of US cancer biotech Acteris. We have proven the technology and candidate programs in vitro and in vivo in both small animal models and primate models.

Gene Editing 105

Gene Editing In-Vivo DNA In-Vitro 105

The Pharma Data

JANUARY 4, 2021

Within the collaboration, ViGeneron will optimize and validate in vitro therapeutic candidates for an undisclosed target to treat inherited eye disease. The companies will work together on the in vivo proof of concept (POC). Biogen has the right to add an additional reserved target within two years after the effective date.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

Delveinsight

JANUARY 12, 2021

Medivir is also eligible to receive milestone payments up to a total of approximately USD 350 million, plus tiered royalties up to mid-teens on net sales upon the commercial approval of the drug. Further, Birinapant also complements the anti-tumor activity of the immune system.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52